SkinBioTherapeutics Past Earnings Performance
Past criteria checks 0/6
SkinBioTherapeutics's earnings have been declining at an average annual rate of -23%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 76.2% per year.
Key information
-23.0%
Earnings growth rate
-15.5%
EPS growth rate
Biotechs Industry Growth | 11.5% |
Revenue growth rate | 76.2% |
Return on equity | -79.0% |
Net Margin | -1,784.7% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Here's Why We're Watching SkinBioTherapeutics' (LON:SBTX) Cash Burn Situation
Mar 28Will SkinBioTherapeutics (LON:SBTX) Spend Its Cash Wisely?
Sep 30Is SkinBioTherapeutics (LON:SBTX) In A Good Position To Deliver On Growth Plans?
Jun 11We Think SkinBioTherapeutics (LON:SBTX) Can Afford To Drive Business Growth
Feb 16We're Not Worried About SkinBioTherapeutics' (LON:SBTX) Cash Burn
Sep 29Companies Like SkinBioTherapeutics (LON:SBTX) Can Afford To Invest In Growth
Mar 23How Much Are SkinBioTherapeutics Plc (LON:SBTX) Insiders Taking Off The Table?
Jan 29Companies Like SkinBioTherapeutics (LON:SBTX) Are In A Position To Invest In Growth
Dec 07Revenue & Expenses BreakdownBeta
How SkinBioTherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -3 | 2 | 1 |
30 Sep 23 | 0 | -3 | 2 | 1 |
30 Jun 23 | 0 | -3 | 2 | 1 |
31 Mar 23 | 0 | -3 | 2 | 1 |
31 Dec 22 | 0 | -3 | 2 | 1 |
30 Sep 22 | 0 | -3 | 2 | 1 |
30 Jun 22 | 0 | -3 | 2 | 1 |
31 Mar 22 | 0 | -2 | 2 | 1 |
31 Dec 21 | 0 | -2 | 1 | 1 |
30 Sep 21 | 0 | -2 | 1 | 1 |
30 Jun 21 | 0 | -1 | 1 | 1 |
31 Mar 21 | 0 | -1 | 1 | 0 |
31 Dec 20 | 0 | -1 | 1 | 0 |
30 Sep 20 | 0 | -1 | 1 | 1 |
30 Jun 20 | 0 | -2 | 1 | 1 |
31 Mar 20 | 0 | -1 | 1 | 1 |
31 Dec 19 | 0 | -1 | 1 | 1 |
30 Sep 19 | 0 | -1 | 1 | 1 |
30 Jun 19 | 0 | -1 | 1 | 1 |
31 Mar 19 | 0 | -1 | 1 | 1 |
31 Dec 18 | 0 | -1 | 1 | 1 |
30 Sep 18 | 0 | -1 | 1 | 1 |
30 Jun 18 | 0 | -1 | 1 | 0 |
31 Mar 18 | 0 | -1 | 1 | 0 |
31 Dec 17 | 0 | -1 | 0 | 0 |
30 Sep 17 | 0 | -1 | 0 | 0 |
30 Jun 17 | 0 | -1 | 0 | 0 |
30 Jun 16 | 0 | 0 | 0 | 0 |
Quality Earnings: SBTX is currently unprofitable.
Growing Profit Margin: SBTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SBTX is unprofitable, and losses have increased over the past 5 years at a rate of 23% per year.
Accelerating Growth: Unable to compare SBTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SBTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: SBTX has a negative Return on Equity (-79.02%), as it is currently unprofitable.